Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (September 2019)

Friday, November 29, 2019

Between January and September 2019, Russia imported a little over 462 bln RUB worth of ready-made pharmaceutical drugs and 91.7 bln RUB worth of in-bulk drugs (customs clearance prices), which is monetary terms (rubles) 22.3% and 12.5% higher than that of the same period in 2018, respectively. The dynamics of the import of ready-made drugs are record-worthy.

The import volume of both ready-made and in-bulk drugs in monetary terms is as high as 80.2 bln RUB, which is the highest since January 2010.

Despite the high dynamics in monetary terms, the dynamics in physical terms are much lower. The dynamics of the import of ready-made drugs in physical terms are +3.8%, with 1.39 bln units. If calculated in minimum dosage units (MDU), the dynamics are +5.5%.

As for in-bulk drugs, the dynamics in physical terms are -17.7%, with 2.63 bln MDUs. However, the total dynamics in physical terms are still positive, +2.9%, with 28.74 bln MDUs.

Among the top 15 importers of ready-made drugs, BMS and Roche showed the highest dynamics in monetary terms, with 4.2 and 2.1 times increases, respectively. The import of two anti-tumor drugs – Opdivo and Yervoy – contributed to BMS’s dynamics: the import of Opdivo has increased by 5 times (to 7.4 bln RUB, customs clearance prices), and the import of Yervoy has grown by 4.5 times (to 1.6 bln RUB). The import of Alecenza contributed to Roche’s dynamics, having increased by 166 times, as well as Tecentriq (a 36 times increase).

As for the top 15 importers of in-bulk drugs, MSD has increased its import by 2.6 times, with 11.8 bln RUB. The import of its Keytruda, which accounts for 74% of the company’s import, has increased by 4.9. The secondary packaging of this drug takes place at R-Pharm’s plant Ortat. MSD is followed by Amgen, with a 2.1 times increase. Vectibix, Xgeva, and Nplate contributed to the company’s dynamics, with 3.5, 2.6, and 1.9 times increases, respectively. The secondary packaging of all three drugs takes place at Pharmeco’s plant Dobrolek.

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia (imports from the EEU countries excluded), free circulation prices including customs clearance and VAT, RUB (January 2018 – September 2019)